Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks
NASDAQ:GNPX

GENPREX 8/9/2024 Earnings Report

GENPREX logo
$0.16 -0.01 (-6.70%)
As of 01:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings History

GENPREX EPS Results

Actual EPS
-$3.00
Consensus EPS
-$2.30
Beat/Miss
Missed by -$0.70
One Year Ago EPS
N/A

GENPREX Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GENPREX Announcement Details

Quarter
Date
8/9/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

GENPREX's next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

GENPREX Earnings Headlines

Genprex receives notice of allowance for multiple patents for Reqorsa
August 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa/ar-AA1KK2QK
Genprex Secures Patent Allowances for Gene Therapy
August 18, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-secures-patent-allowances-for-gene-therapy?utm_source=marketbeat.com&utm_medium=referral
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
August 29 at 2:00 AM  |  The Oxford Club (Ad)
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
August 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-notice-of-allowance-for-multiple-patents-for-reqorsa-gene-therapy-with-pd-l1-and-pd-1-antibodies-to-treat-cancers-302531812.html
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
August 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-issues-stockholder-letter-and-provides-2025-corporate-update-302519361.html
Genprex, Inc. (GNPX) Latest Stock News & Headlines - Yahoo Finance
June 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/GNPX/news/
See More GENPREX Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GENPREX? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GENPREX and other key companies, straight to your email.

About GENPREX

GENPREX (NASDAQ:GNPX), Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

View GENPREX Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles